These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 24520210)

  • 21. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
    Viey E; Fromont G; Escudier B; Morel Y; Da Rocha S; Chouaib S; Caignard A
    J Immunol; 2005 Feb; 174(3):1338-47. PubMed ID: 15661891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Dual Roles of Human γδ T Cells: Anti-Tumor or Tumor-Promoting.
    Li Y; Li G; Zhang J; Wu X; Chen X
    Front Immunol; 2020; 11():619954. PubMed ID: 33664732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma.
    Alexander AA; Maniar A; Cummings JS; Hebbeler AM; Schulze DH; Gastman BR; Pauza CD; Strome SE; Chapoval AI
    Clin Cancer Res; 2008 Jul; 14(13):4232-40. PubMed ID: 18594005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repertoire development and the control of cytotoxic/effector function in human gammadelta T cells.
    Urban EM; Chapoval AI; Pauza CD
    Clin Dev Immunol; 2010; 2010():732893. PubMed ID: 20396597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Harnessing γδ T cells in anticancer immunotherapy.
    Hannani D; Ma Y; Yamazaki T; Déchanet-Merville J; Kroemer G; Zitvogel L
    Trends Immunol; 2012 May; 33(5):199-206. PubMed ID: 22364810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells.
    Toutirais O; Cabillic F; Le Friec G; Salot S; Loyer P; Le Gallo M; Desille M; de La Pintière CT; Daniel P; Bouet F; Catros V
    Eur J Immunol; 2009 May; 39(5):1361-8. PubMed ID: 19404979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses.
    Brandes M; Willimann K; Bioley G; Lévy N; Eberl M; Luo M; Tampé R; Lévy F; Romero P; Moser B
    Proc Natl Acad Sci U S A; 2009 Feb; 106(7):2307-12. PubMed ID: 19171897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal Cell Carcinoma-Infiltrating CD3
    Lee HW; Park C; Joung JG; Kang M; Chung YS; Oh WJ; Yeom SY; Park WY; Kim TJ; Seo SI
    Curr Issues Mol Biol; 2021 May; 43(1):226-239. PubMed ID: 34071865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting gamma delta T cells for cancer immunotherapy: bench to bedside.
    Gogoi D; Chiplunkar SV
    Indian J Med Res; 2013 Nov; 138(5):755-61. PubMed ID: 24434328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gammadelta T cell activation or anergy during infections: the role of nonpeptidic TCR ligands and HLA class I molecules.
    Poccia F; Malkovsky M; Gougeon ML; Bonneville M; Lopez-Botet M; Fournié JJ; Colizzi V
    J Leukoc Biol; 1997 Sep; 62(3):287-91. PubMed ID: 9307066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of gammadelta T lymphocytes in tumor defense.
    Zocchi MR; Poggi A
    Front Biosci; 2004 Sep; 9():2588-604. PubMed ID: 15358583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of Vdelta1 gammadelta T cell activation by microbial components.
    Das H; Sugita M; Brenner MB
    J Immunol; 2004 Jun; 172(11):6578-86. PubMed ID: 15153472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro.
    Liu Z; Guo BL; Gehrs BC; Nan L; Lopez RD
    J Urol; 2005 May; 173(5):1552-6. PubMed ID: 15821484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human gammadelta-T cells in adoptive immunotherapy of malignant and infectious diseases.
    Lopez RD
    Immunol Res; 2002; 26(1-3):207-21. PubMed ID: 12403359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human γδ T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias.
    Pistoia V; Tumino N; Vacca P; Veneziani I; Moretta A; Locatelli F; Moretta L
    Front Immunol; 2018; 9():984. PubMed ID: 29867961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of cytokine producing activity of intestinal intraepithelial T cells from TCR beta-chain and delta-chain mutant mice.
    Kohyama M; Hachimura S; Nanno M; Ishikawa H; Kaminogawa S
    Microbiol Immunol; 1997; 41(4):353-9. PubMed ID: 9159410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uncoupling between immunological synapse formation and functional outcome in human gamma delta T lymphocytes.
    Favier B; Espinosa E; Tabiasco J; Dos Santos C; Bonneville M; Valitutti S; Fournié JJ
    J Immunol; 2003 Nov; 171(10):5027-33. PubMed ID: 14607899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human Vδ2 T Cells and Their Versatility for Immunotherapeutic Approaches.
    Sanz M; Mann BT; Chitrakar A; Soriano-Sarabia N
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
    Braza MS; Klein B
    Br J Haematol; 2013 Jan; 160(2):123-32. PubMed ID: 23061882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.
    Deniger DC; Maiti SN; Mi T; Switzer KC; Ramachandran V; Hurton LV; Ang S; Olivares S; Rabinovich BA; Huls MH; Lee DA; Bast RC; Champlin RE; Cooper LJ
    Clin Cancer Res; 2014 Nov; 20(22):5708-19. PubMed ID: 24833662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.